Compositions and methods for in vivo imaging

Patent metadata

Field	Value
Publication number	US-9649394-B2
Application number	US-201113988790-A
Country	US
Kind code	B2
Filing date	Nov 22, 2011
Priority date	Nov 22, 2010
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. A method for detecting a cancer in a subject, the method comprising:
(a) administering to a subject an effective amount of a compound selected from:

or a pharmaceutically acceptable salt form thereof, and
(b) detecting the compound in the subject.

4. The method of claim 3 , wherein detecting the compound comprises using fluorescence detection, chemiluminescence detection, magnetic resonance imaging, nuclear magnetic resonance imaging, positron emission tomography, and single-photon emission computed tomography.

5. The method of claim 3 , wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, and breast cancer.

6. The method of claim 3 , wherein the compound is administered before and after surgical removal of the cancer.

7. A method for monitoring the cancer treatment of a patient, the method comprising:
(a) administering to the patient, prior to a treatment, an effective amount of a compound selected from:

or a pharmaceutically acceptable salt form thereof, and
imaging the patient;
(b) administering to the patient, at a point following treatment, an effective amount the compound and imaging the patient; and
(c) comparing the image collected in step (a) with the image collected in step (b) to monitor the treatment.

8. The method of claim 7 , wherein the treatment comprises administration of an anti-cancer agent.

9. The method of claim 7 , wherein the method further comprises: administering to the patient an effective amount of the compound during treatment and imaging the patient.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The method of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The method of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Reiner Thomas
• Keliher Edmund J
• Weissleder Ralph
• Massachusetts Gen Hospital

Inventors

• Reiner Thomas
• Keliher Edmund J
• Weissleder Ralph

Classifications

• A61K51/0459 Primary

  having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title

• A61K49/0021

  the fluorescent group being a small organic molecule · CPC title

• A61K51/1251

  micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules · CPC title